Could a migraine drug stop dizziness fast?
NCT ID NCT07435090
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether rimegepant, a drug used for migraines, can quickly reduce dizziness from conditions like vestibular migraine. About 370 adults with moderate to severe dizziness will receive either rimegepant plus betahistine or betahistine alone. The main goal is to see if dizziness drops from moderate/severe to none/mild within one hour.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rimegepant
- What this could lead to
- If it works, this could provide a new, fast-acting treatment option for acute dizziness attacks.
- What could go wrong
- This is an early-phase trial (Phase 2/3) with a moderate size, so results may not confirm effectiveness or safety for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BENIGN RECURRENT VERTIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a symptom registry unmask hidden migraine variants?
- Could a stick of gum soothe a spinning world?
- Can a Dual-Task test predict falls in the elderly?
- Wearable patch aims to catch hidden heart rhythms that holter monitors miss
- New study targets lingering concussion symptoms in teens
- Can your balance predict motion sickness? new study investigates